2,7-Diazabicyclo[2.2.1]heptanes: novel asymmetric access and controlled bridge-opening
Research output: Contribution to journal › Article
Colleges, School and Institutes
- Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK
Organocatalysed asymmetric Michael additions of substituted triketopiperazines to enones afford products in high yield and enantiomeric ratio (er). Further modification delivers products possessing natural product (NP) scaffolds including diazabicyclo[2.2.1]heptane, prolinamide and harmicine.
|Number of pages||4|
|Publication status||Published - 12 Mar 2019|